Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma

✍ Scribed by Younes, A.; Kim, S.; Romaguera, J.; Copeland, A.; Farial, S. d. C.; Kwak, L. W.; Fayad, L.; Hagemeister, F.; Fanale, M.; Neelapu, S.; Lambert, J. M.; Morariu-Zamfir, R.; Payrard, S.; Gordon, L. I.

• Book ID: 125531663
• Publisher: American Society of Clinical Oncology
• Year: 2012
• Tongue: English
• Weight: 268 KB
• Volume: 30
• Category: Article
• ISSN: 0732-183X
• DOI: 10.1200/JCO.2011.39.4403